REGENXBIO FY2026 EPS Forecast Boosted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Research analysts at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for shares of REGENXBIO in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will earn $0.28 per share for the year, up from their previous estimate of ($0.52). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.85) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2027 earnings at ($0.14) EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.21 EPS.

Several other analysts have also issued reports on RGNX. StockNews.com lowered shares of REGENXBIO from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. Raymond James restated an “outperform” rating and set a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of REGENXBIO in a research report on Wednesday, January 15th. Morgan Stanley restated an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Finally, Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and an average target price of $34.82.

REGENXBIO Stock Performance

Shares of REGENXBIO stock opened at $7.82 on Monday. REGENXBIO has a 52-week low of $6.56 and a 52-week high of $28.80. The company has a fifty day moving average of $8.20 and a 200-day moving average of $10.16. The stock has a market capitalization of $387.40 million, a price-to-earnings ratio of -1.55 and a beta of 1.29.

Institutional Trading of REGENXBIO

Several large investors have recently bought and sold shares of the company. Barclays PLC lifted its stake in shares of REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after purchasing an additional 67,948 shares during the period. Assenagon Asset Management S.A. lifted its position in REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after buying an additional 296,700 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 17,533 shares in the last quarter. FMR LLC grew its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the period. Finally, Stifel Financial Corp increased its stake in shares of REGENXBIO by 13.3% in the 3rd quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after acquiring an additional 17,563 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.